Clopidogrel Taw Pharma (previously Clopidogrel Mylan)

Authorised

This medicine is authorised for use in the European Union

clopidogrel

Overview

Clopidogrel Taw Pharma is a medicine used to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in adults who have:

• recently had a myocardial infarction (heart attack). Clopidogrel Taw Pharma can be started between a few days and 35 days after the attack;
• recently had an ischaemic stroke (stroke caused by insufficient blood supply to part of the brain). Clopidogrel Taw Pharma can be started between seven days and six months after the stroke;
• peripheral arterial disease (problems with blood flow in the arteries);
• a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots). Acute coronary syndrome is a group of heart problems that include unstable angina (a severe type of chest pain) and certain types of heart attack. Some of these patients may have had a stent (a short tube) inserted into an artery to prevent it from closing up.

Clopidogrel Taw Pharma is also used to prevent problems caused by blood clots in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin. It is used in patients who have at least one risk factor for events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.

Clopidogrel Taw Pharma contains the active substance clopidogrel and is a ‘generic medicine’. This means that Clopidogrel Taw Pharma contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Plavix. For more information on generic medicines, see the question-and-answer document here.

How is Clopidogrel Taw Pharma used?

Clopidogrel Taw Pharma is available as tablets. The standard dose is 75 mg once a day.

In acute coronary syndrome, treatment generally starts with a loading dose of 300 mg. This is then followed by the standard 75 mg dose once a day for between 4 weeks and up to 12 months.

Clopidogrel Taw Pharma can only be obtained with a prescription.

For more information about using Clopidogrel Taw Pharma, see the package leaflet or contact your doctor or pharmacist.

How does Clopidogrel Taw Pharma work?

The active substance in Clopidogrel Taw Pharma, clopidogrel, is an antiplatelet medicine. This means that it helps to prevent components in the blood called platelets from sticking together and forming clots. Clopidogrel blocks a substance called ADP from attaching to a receptor (target) on the surface of platelets. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

How has Clopidogrel Taw Pharma been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Plavix, and do not need to be repeated for Clopidogrel Taw Pharma.

As for every medicine, the company provided data on the quality of Clopidogrel Taw Pharma. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

What are the benefits and risks of Clopidogrel Taw Pharma?

Because Clopidogrel Taw Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why is Clopidogrel Taw Pharma authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Clopidogrel Taw Pharma has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the Agency’s view was that, as for Plavix, the benefits of Clopidogrel Taw Pharma outweigh the identified risks and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of Clopidogrel Taw Pharma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Clopidogrel Taw Pharma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Clopidogrel Taw Pharma are continuously monitored. Suspected side effects reported with Clopidogrel Taw Pharma are carefully evaluated and any necessary action taken to protect patients.

Other information about Clopidogrel Taw Pharma

Clopidogrel Mylan received a marketing authorisation valid throughout the EU on 21 September 2009. The name of the medicine was changed to Clopidogrel Taw Pharma on 1 October 2021.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) : EPAR - Summary for the public

Product information

Clopidogrel Taw Pharma : EPAR - Product information

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Clopidogrel Taw Pharma (previously Clopidogrel Mylan)
• Active substance:
  clopidogrel hydrochloride
• International non-proprietary name (INN) or common name:
  clopidogrel
• Therapeutic area (MeSH):
  • Peripheral Vascular Diseases
  • Stroke
  • Myocardial Infarction
  • Acute Coronary Syndrome
• Anatomical therapeutic chemical (ATC) code:
  B01AC04

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Secondary prevention of atherothrombotic events Clopidogrel is indicated in:  - Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. - Adult patients suffering from acute coronary syndrome:    - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).     - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS) Clopidogrel in combination with ASA is indicated in: - Adult patients with moderate to high-risk TIA (ABCD2  score ?4) or minor IS (NIHSS  ?3) within 24 hours of either the TIA or IS event.  Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. For further information please refer to section 5.1.

Authorisation details

• EMA product number:
  EMEA/H/C/001134
• Generic:

  This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

• Marketing authorisation holder:
  Taw Pharma (Ireland) Limited

  104 Baggot Street Lower; Dublin 2; Co. Dublin; D02 Y940; Ireland;

• Opinion adopted:
  25/06/2009
• Marketing authorisation issued:
  21/09/2009
• Revision:
  21

Assessment history

Changes since initial authorisation of medicine

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Clopidogrel Mylan : EPAR - Public assessment report

Committee for medicinal products for human use summary of positive opinion for Clopidogrel Mylan

Reference Number: EMEA/CHMP/379519/2009